Related content

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer 2

By McLeod D.   Zinner N.   Tomera K.   Gleason D.   Fotheringham N.   Campion M.   Garnick M.B.   for the Abarelix Study Group  

Urology, Vol. 58, Iss. 5, 2001-11 ,pp. : 756-761

Elsevier

Access to resources Recommend Favorite

Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer

By Incrocci L.   Hop W.C.J.   Slob A.K.  

Urology, Vol. 62, Iss. 1, 2003-07 ,pp. : 116-120

Elsevier

Access to resources Recommend Favorite

Open-label phase II study of ZD0473 in patients with metastatic hormone-refractory prostate cancer

By Tyrrell C.   Bullard S.   Barber J.   Graham J.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 158-158

Elsevier

Access to resources Recommend Favorite

Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study

By van Kerrebroeck P.   Jardin A.   van Cangh P.   Laval K.U.   The ALFORTI Study Group  

European Urology, Vol. 41, Iss. 1, 2002-01 ,pp. : 54-61

Elsevier

Access to resources Recommend Favorite

Efficacy and safety of daily intake of apomorphine SL in men affected by erectile dysfunction and mild hyperprolactinemia: a prospective, open-label, pilot study

By Caruso S.   Intelisano G.   Farina M.   DiMari L.   Agnello C.   Giammusso B.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 922-927

Elsevier

Access to resources Recommend Favorite